董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick J. Beyer | 男 | Director | 60 | 28.25万美元 | 14.36 | 2026-03-01 |
| Philip G. Cowdy | 男 | Director | 59 | 24.50万美元 | 3.23 | 2026-03-01 |
| Susan M. Stalnecker | 女 | Director | 73 | 30.00万美元 | 13.82 | 2026-03-01 |
| Guido J. Neels | 男 | Director | 78 | 27.75万美元 | 11.75 | 2026-03-01 |
| Mary Kay Ladone | 女 | Director | 60 | 29.00万美元 | 11.13 | 2026-03-01 |
| Michelle McMurry Heath | 女 | Director | 56 | 28.00万美元 | 7.73 | 2026-03-01 |
| Ajay Dhankhar | 男 | Director | 55 | 未披露 | 未持股 | 2026-03-01 |
| Robert E. Claypoole | 男 | President, Chief Executive Officer and Director | 54 | 429.91万美元 | 60.74 | 2026-03-01 |
| Guy P. Nohra | 男 | Director | 67 | 27.50万美元 | 14.89 | 2026-03-01 |
| Martin P. Sutter | 男 | Director | 71 | 21.50万美元 | 1313.88 | 2026-03-01 |
| John A. Bartholdson | 男 | Director | 55 | 29.00万美元 | 705.13 | 2026-03-01 |
| William A. Hawkins | 男 | Chairperson and Director | 72 | 38.00万美元 | 29.76 | 2026-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katrina Church | 女 | Chief Compliance Officer and Senior Vice President | 65 | 未披露 | 未持股 | 2026-03-01 |
| Robert E. Claypoole | 男 | President, Chief Executive Officer and Director | 54 | 429.91万美元 | 60.74 | 2026-03-01 |
| Mark L. Singleton | 男 | Chief Financial Officer and Senior Vice President | 57 | 189.71万美元 | 61.43 | 2026-03-01 |
董事简历
中英对照 | 中文 | 英文- Patrick J. Beyer
-
Patrick J. Beyer于2014年12月加入公司担任CONMED International总裁。加入CONMED之前，Beyer从2010年到2014年担任ICNet（一家私营感染控制软件公司）首席执行官，公司于2014年被卖掉。在此之前，Beyer在Stryker Corporation任职了21年，2005年到2009年领导Stryker Europe；2002年到2005年领导Stryker UK, South Africa and Ireland；1999年到2002年领导Stryker Medical。Beyer毕业于Kalamazoo College，持有经济学文学学士学位；持有Western Michigan University金融工商管理硕士学位；Harvard Business School高级管理项目毕业生。
Patrick J. Beyer joined the Company as President of CONMED International in December 2014. Prior to joining CONMED, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation where he led Stryker Europe from 2005-2009; Stryker UK, South Africa and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002. Mr. Beyer graduated from Kalamazoo College with a BA in Economics, Western Michigan University with an MBA in Finance and Harvard Business School's Advanced Management Program. - Patrick J. Beyer于2014年12月加入公司担任CONMED International总裁。加入CONMED之前，Beyer从2010年到2014年担任ICNet（一家私营感染控制软件公司）首席执行官，公司于2014年被卖掉。在此之前，Beyer在Stryker Corporation任职了21年，2005年到2009年领导Stryker Europe；2002年到2005年领导Stryker UK, South Africa and Ireland；1999年到2002年领导Stryker Medical。Beyer毕业于Kalamazoo College，持有经济学文学学士学位；持有Western Michigan University金融工商管理硕士学位；Harvard Business School高级管理项目毕业生。
- Patrick J. Beyer joined the Company as President of CONMED International in December 2014. Prior to joining CONMED, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation where he led Stryker Europe from 2005-2009; Stryker UK, South Africa and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002. Mr. Beyer graduated from Kalamazoo College with a BA in Economics, Western Michigan University with an MBA in Finance and Harvard Business School's Advanced Management Program.
- Philip G. Cowdy
-
Philip G. Cowdy，自2012年1月起担任Bioventus LLC的经理，是其审计委员会的成员。他是Smith & Nephew（全球医疗技术公司）的企业事务与战略规划主管。自2008年加入Smith & Nephew起，他担任了企业事务集团主管和投资者关系主管等职位。在加入Smith & Nephew之前，他担任Deutsche Bank的高级主管13年，为英国地区多个企业提供企业财务和股权资本市场方面的咨询服务。他获得了英国Durham University的自然科学学士学位。
Philip G. Cowdy has served as a member of our board of directors since September 2020. Mr. Cowdy is the Chief Business Development and Corporate Affairs Officer for Smith & Nephew plc. Since joining Smith & Nephew plc in June 2008 he has also served as Executive Vice President of Business Development and Corporate Affairs, Head of Corporate Affairs and Strategic Planning, Group Director of Corporate Affairs and Director of Investor Relations. Prior to joining Smith & Nephew plc, Mr. Cowdy served as a Senior Director at Deutsche Bank for 13 years, providing corporate finance and equity capital markets advice to a variety of UK-based companies. Mr. Cowdy is currently a member of the board of managers of Bioventus LLC, which he has served on from January 2012 to October 2017 and again from July 2018 and he has served as a member of the Audit, Compliance and Quality Committee. Mr. Cowdy received his Bachelor of Science in Natural Sciences from Durham University UK and is a qualified chartered accountant. - Philip G. Cowdy，自2012年1月起担任Bioventus LLC的经理，是其审计委员会的成员。他是Smith & Nephew（全球医疗技术公司）的企业事务与战略规划主管。自2008年加入Smith & Nephew起，他担任了企业事务集团主管和投资者关系主管等职位。在加入Smith & Nephew之前，他担任Deutsche Bank的高级主管13年，为英国地区多个企业提供企业财务和股权资本市场方面的咨询服务。他获得了英国Durham University的自然科学学士学位。
- Philip G. Cowdy has served as a member of our board of directors since September 2020. Mr. Cowdy is the Chief Business Development and Corporate Affairs Officer for Smith & Nephew plc. Since joining Smith & Nephew plc in June 2008 he has also served as Executive Vice President of Business Development and Corporate Affairs, Head of Corporate Affairs and Strategic Planning, Group Director of Corporate Affairs and Director of Investor Relations. Prior to joining Smith & Nephew plc, Mr. Cowdy served as a Senior Director at Deutsche Bank for 13 years, providing corporate finance and equity capital markets advice to a variety of UK-based companies. Mr. Cowdy is currently a member of the board of managers of Bioventus LLC, which he has served on from January 2012 to October 2017 and again from July 2018 and he has served as a member of the Audit, Compliance and Quality Committee. Mr. Cowdy received his Bachelor of Science in Natural Sciences from Durham University UK and is a qualified chartered accountant.
- Susan M. Stalnecker
-
Susan M. Stalnecker受雇于E.I. du Pont de Nemours＆Co.于1977年至2016年期间担任过多个高级职位，包括担任副总裁兼财务主管10年，最近担任企业生产力和酒店业副总裁。 Stalnecker女士曾于2001年12月至2009年1月担任PPL电力公司的公共控股公司PPL Corporation的董事会成员，并于2003年至2015年在杜克大学董事会任职。她目前担任董事会成员。 杜克大学健康系统公司董事和审计委员会。
Susan M. Stalnecker,was employed by E.I. du Pont de Nemours & Co. (currently DuPont de Nemours, Inc.) from 1977 to 2016, serving in numerous senior roles during her tenure, including ten years as Vice President and Treasurer and most recently as Vice President, Corporate Productivity and Hospitality. Ms. Stalnecker previously served on the Board of Directors of PPL Corporation, a public holding company of PPL Electric Utilities Corporation, from December 2001 to January 2009, and on the Board of Trustees of Duke University from 2003 to 2015. She currently serves on the Board of Directors of Bioventus Inc., where she is also the chair of the Audit Committee. In addition, Ms. Stalnecker serves on the Board of Directors of the Macquarie Optimum Fund Trust, where she is the chair of the Audit Committee, and on the Board of Directors of the Duke University Health System, Inc., where she is the Chair of the Audit and Compliance Committee. She is also a Senior Adviser to the Boston Consulting Group, specializing in restructuring, finance transactions, activism and executive coaching. - Susan M. Stalnecker受雇于E.I. du Pont de Nemours＆Co.于1977年至2016年期间担任过多个高级职位，包括担任副总裁兼财务主管10年，最近担任企业生产力和酒店业副总裁。 Stalnecker女士曾于2001年12月至2009年1月担任PPL电力公司的公共控股公司PPL Corporation的董事会成员，并于2003年至2015年在杜克大学董事会任职。她目前担任董事会成员。 杜克大学健康系统公司董事和审计委员会。
- Susan M. Stalnecker,was employed by E.I. du Pont de Nemours & Co. (currently DuPont de Nemours, Inc.) from 1977 to 2016, serving in numerous senior roles during her tenure, including ten years as Vice President and Treasurer and most recently as Vice President, Corporate Productivity and Hospitality. Ms. Stalnecker previously served on the Board of Directors of PPL Corporation, a public holding company of PPL Electric Utilities Corporation, from December 2001 to January 2009, and on the Board of Trustees of Duke University from 2003 to 2015. She currently serves on the Board of Directors of Bioventus Inc., where she is also the chair of the Audit Committee. In addition, Ms. Stalnecker serves on the Board of Directors of the Macquarie Optimum Fund Trust, where she is the chair of the Audit Committee, and on the Board of Directors of the Duke University Health System, Inc., where she is the Chair of the Audit and Compliance Committee. She is also a Senior Adviser to the Boston Consulting Group, specializing in restructuring, finance transactions, activism and executive coaching.
- Guido J. Neels
-
Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium. - Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
- Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium.
- Mary Kay Ladone
-
Mary Kay Ladone当选为高级副总裁，公司发展，战略和投资者关系，自2018年12月起生效。自2016年7月加入Hill-Rom以来，她曾担任投资者关系部Vice President。加入Hillrom公司之前，她曾担任Baxalta股份有限公司公司的投资者关系高级副总裁，。此前，她曾担任Baxter International公司的多种高级财务、业务开发和投资者关系职务。
Mary Kay Ladone has been a member of Kestra Medical Technologies, Ltd.'s Board since 2025 and is also the chair of Kestra Medical Technologies, Ltd.'s audit committee and a member of Kestra Medical Technologies, Ltd.'s nominating and corporate governance committee. Additionally, Ms. Ladone was a member of the board of directors of Kestra Medical Technologies, Ltd.'s subsidiary, Kestra Medical Technologies, Inc., from 2022 to 2025. Ms. Ladone is an accomplished executive with over 35 years of experience serving large global healthcare companies. Ms. Ladone served as senior vice president of corporate development, strategy and investor relations at Hill Rom Holdings, Inc. ("Hilrom"), a medical technology company, from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president and corporate officer, investor relations of Baxalta, Inc. (formerly NYSE: BXLT), a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc. (NYSE: BAX) ("Baxter"), and from 1988 to 2015 served in several progressive financial, operational and communication roles at Baxter. Ms. Ladone currently serves on the board of directors of Novanta Inc. (Nasdaq: NOVT), Bioventus LLC (Nasdaq: BVS) and Inogen, Inc. (Nasdaq: INGN). Ms. Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame. - Mary Kay Ladone当选为高级副总裁，公司发展，战略和投资者关系，自2018年12月起生效。自2016年7月加入Hill-Rom以来，她曾担任投资者关系部Vice President。加入Hillrom公司之前，她曾担任Baxalta股份有限公司公司的投资者关系高级副总裁，。此前，她曾担任Baxter International公司的多种高级财务、业务开发和投资者关系职务。
- Mary Kay Ladone has been a member of Kestra Medical Technologies, Ltd.'s Board since 2025 and is also the chair of Kestra Medical Technologies, Ltd.'s audit committee and a member of Kestra Medical Technologies, Ltd.'s nominating and corporate governance committee. Additionally, Ms. Ladone was a member of the board of directors of Kestra Medical Technologies, Ltd.'s subsidiary, Kestra Medical Technologies, Inc., from 2022 to 2025. Ms. Ladone is an accomplished executive with over 35 years of experience serving large global healthcare companies. Ms. Ladone served as senior vice president of corporate development, strategy and investor relations at Hill Rom Holdings, Inc. ("Hilrom"), a medical technology company, from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president and corporate officer, investor relations of Baxalta, Inc. (formerly NYSE: BXLT), a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc. (NYSE: BAX) ("Baxter"), and from 1988 to 2015 served in several progressive financial, operational and communication roles at Baxter. Ms. Ladone currently serves on the board of directors of Novanta Inc. (Nasdaq: NOVT), Bioventus LLC (Nasdaq: BVS) and Inogen, Inc. (Nasdaq: INGN). Ms. Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame.
- Michelle McMurry Heath
-
Michelle Mcmurry Heath于2020年至2022年担任全球最大的生物技术倡导团体生物技术创新组织（Biotechnology Innovation Organization）的总裁兼首席执行官。2014年至2020年，McMurry Health博士曾在强生公司任职，担任医疗器械公司证据生成全球负责人，然后担任全球外部创新副总裁和监管科学全球领导者。在J&J任职之前，McMurry Health博士也是政府的关键科学政策领导人，对国家科学基金会的政策、计划和人员进行了全面分析。随后，奥巴马总统任命她为美国食品和药物管理局设备和放射健康中心的副科学主任。McMurry Health博士是阿斯彭研究所健康、生物医学科学和社会政策项目的创始主任，并从Robert Wood Johnson Foundation接受了科学政策方面的早期培训。McMurry Health博士还担任上市公司Bioventus的董事会成员。她在哈佛大学获得了生物化学文学士学位，在杜克大学医学科学家培训项目获得了博士/博士学位，成为第一位从这一著名项目毕业的非裔美国人，在担任政府和行业的政策和领导角色之前，她在研究团队工作了12年。
Michelle McMurry Heath has served as the Chief Executive Officer of BioTechquity Clinical, a novel clinical research organization designed to help drug and device innovators enroll and conduct diverse clinical trials, since founding the firm in 2024. Prior to her current position, Dr. McMurry Heath was a consultant to the biotechnology indtry and most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization, the world's largest biotechnology advocacy group, from 2020 to 2022. Dr. McMurry Health was also previoly with Johnson & Johnson (J&J) from 2014 to 2020, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Before joining J&J, Dr. McMurry Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health. Dr. McMurry Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation. Dr. McMurry Heath also serves on the board of directors at publicly traded Biovent Inc. She received her Bachelor of Arts degree in biochemistry from Harvard University and her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African American to graduate from the prestigio program. Dr. McMurry Heath spent 12 years working at the research bench before taking policy and leadership roles in government and indtry. - Michelle Mcmurry Heath于2020年至2022年担任全球最大的生物技术倡导团体生物技术创新组织（Biotechnology Innovation Organization）的总裁兼首席执行官。2014年至2020年，McMurry Health博士曾在强生公司任职，担任医疗器械公司证据生成全球负责人，然后担任全球外部创新副总裁和监管科学全球领导者。在J&J任职之前，McMurry Health博士也是政府的关键科学政策领导人，对国家科学基金会的政策、计划和人员进行了全面分析。随后，奥巴马总统任命她为美国食品和药物管理局设备和放射健康中心的副科学主任。McMurry Health博士是阿斯彭研究所健康、生物医学科学和社会政策项目的创始主任，并从Robert Wood Johnson Foundation接受了科学政策方面的早期培训。McMurry Health博士还担任上市公司Bioventus的董事会成员。她在哈佛大学获得了生物化学文学士学位，在杜克大学医学科学家培训项目获得了博士/博士学位，成为第一位从这一著名项目毕业的非裔美国人，在担任政府和行业的政策和领导角色之前，她在研究团队工作了12年。
- Michelle McMurry Heath has served as the Chief Executive Officer of BioTechquity Clinical, a novel clinical research organization designed to help drug and device innovators enroll and conduct diverse clinical trials, since founding the firm in 2024. Prior to her current position, Dr. McMurry Heath was a consultant to the biotechnology indtry and most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization, the world's largest biotechnology advocacy group, from 2020 to 2022. Dr. McMurry Health was also previoly with Johnson & Johnson (J&J) from 2014 to 2020, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Before joining J&J, Dr. McMurry Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health. Dr. McMurry Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation. Dr. McMurry Heath also serves on the board of directors at publicly traded Biovent Inc. She received her Bachelor of Arts degree in biochemistry from Harvard University and her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African American to graduate from the prestigio program. Dr. McMurry Heath spent 12 years working at the research bench before taking policy and leadership roles in government and indtry.
- Ajay Dhankhar
-
Ajay Dhankhar，自2025年6月起担任施乐辉 PLC（NYSE：SNN）首席企业发展与战略官。Dhankhar博士于2024年7月创立了Bluish Capital，这是一家战略和财务咨询公司，专注于部署成长资本以支持高质量，最近FDA批准了资产，并担任其管理合伙人，直到被任命为施乐辉。2022年7月至2024年6月，Dhankhar博士在Lazard Ltd（NYSE：LAZ）的财务咨询医疗保健集团担任董事总经理，担任医疗技术、诊断和工具的全球主管。在加入Lazard之前，Dhankhar博士在麦肯锡公司担任了25年的多个领导职务，包括最近的高级合伙人，以及生命科学战略和并购全球主管以及生命科学研发全球主管。Dhankhar博士拥有安杰洛州立大学物理和计算机科学学士学位，耶鲁大学分子生物物理和生物化学博士学位。
Ajay Dhankhar,has served as the Chief Corporate Development & Strategy Officer of Smith & Nephew plc (NYSE: SNN) since June 2025. Dr. Dhankhar founded Bluish Capital in July 2024, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets, and served as its Managing Partner until his appointment to Smith & Nephew. From July 2022 to June 2024, Dr. Dhankhar served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE: LAZ), where he was the Global Head of Medical Technology, Diagnostics and Tools. Prior to joining Lazard, Dr. Dhankhar held multiple leadership roles at the McKinsey & Company over a span of 25 years, including, most recently, Senior Partner, as well as Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D. Dr. Dhankhar has a B.S. in Physics and Computer Science from Angelo State University and a PhD in Molecular Biophysics and Biochemistry from Yale University. - Ajay Dhankhar，自2025年6月起担任施乐辉 PLC（NYSE：SNN）首席企业发展与战略官。Dhankhar博士于2024年7月创立了Bluish Capital，这是一家战略和财务咨询公司，专注于部署成长资本以支持高质量，最近FDA批准了资产，并担任其管理合伙人，直到被任命为施乐辉。2022年7月至2024年6月，Dhankhar博士在Lazard Ltd（NYSE：LAZ）的财务咨询医疗保健集团担任董事总经理，担任医疗技术、诊断和工具的全球主管。在加入Lazard之前，Dhankhar博士在麦肯锡公司担任了25年的多个领导职务，包括最近的高级合伙人，以及生命科学战略和并购全球主管以及生命科学研发全球主管。Dhankhar博士拥有安杰洛州立大学物理和计算机科学学士学位，耶鲁大学分子生物物理和生物化学博士学位。
- Ajay Dhankhar,has served as the Chief Corporate Development & Strategy Officer of Smith & Nephew plc (NYSE: SNN) since June 2025. Dr. Dhankhar founded Bluish Capital in July 2024, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets, and served as its Managing Partner until his appointment to Smith & Nephew. From July 2022 to June 2024, Dr. Dhankhar served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE: LAZ), where he was the Global Head of Medical Technology, Diagnostics and Tools. Prior to joining Lazard, Dr. Dhankhar held multiple leadership roles at the McKinsey & Company over a span of 25 years, including, most recently, Senior Partner, as well as Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D. Dr. Dhankhar has a B.S. in Physics and Computer Science from Angelo State University and a PhD in Molecular Biophysics and Biochemistry from Yale University.
- Robert E. Claypoole
-
Robert E. Claypoole，于2024年1月加入Bioventus，担任总裁兼首席执行官，并担任Bioventus Inc.董事会成员。Claypoole先生从世界领先的医疗产品和解决方案公司M lnlycke Health Care（“M lnlycke”）加入Bioventus，自2021年7月起担任伤口护理执行副总裁。在担任这一职务时，克莱普尔先生对一项价值12亿美元的业务负有全部责任。在此之前，Claypoole先生曾于2017年3月至2021年7月在M lnlycke担任多个领导职务，包括M lnlycke执行副总裁兼美国总裁，以及M lnlycke Health Care US，LLC和M lnlycke Manufacturing US，LLC的官员。在2017年加入M lnlycke之前，Claypoole先生在被美敦力收购之前，曾在全球医疗保健技术公司美敦力有限公司（现为美敦力 PLC（NYSE：MDT））和Covidien担任过各种领导职务。Claypoole先生曾任肥胖与代谢健康全球副总裁兼总经理（2016年4月至2017年3月）和软组织修复与止血剂业务全球副总裁兼总经理（2012年12月至2016年4月）。在此之前，他在法国Trevoux担任全球营销副总裁后担任副总裁，执行运营。在法国任职之前，Claypoole先生是该公司内机和智能设备业务的美国市场营销副总裁。在2007年加入Covidien之前，Claypoole先生曾在强生的视力保健部门担任过各种营销职务，责任越来越大。Claypoole先生曾在ZetrOz Inc.（2014年1月至2016年1月）和围术期注册护士协会（2017年12月至2020年12月）的董事会任职。Claypoole先生获得了康奈尔大学的文学学士学位和工商管理硕士学位。
Robert E. Claypoole,joined Bioventus in January 2024 as President and Chief Executive Officer and as a member of Bioventus Inc. Board. Mr. Claypoole joined Bioventus from Mlnlycke Health Care ("Mlnlycke"), a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care since July 2021. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business. Before that, Mr. Claypoole served in several leadership positions with Mlnlycke from March 2017 to July 2021, including Executive Vice President and President, US for Mlnlycke and as an Officer of Mlnlycke Health Care US, LLC and Mlnlycke Manufacturing US, LLC. Prior to joining Mlnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic Ltd. (now Medtronic plc (NYSE: MDT)), a global healthcare technology company, and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health (April 2016 to March 2017) and Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business (December 2012 to April 2016). Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company's Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson's Vision Care division. Mr. Claypoole previously served on the board of directors of ZetrOz Inc. (January 2014 to January 2016) and the Association of periOperative Registered Nurses (December 2017 to December 2020). Mr. Claypoole received his Bachelor of Arts and his Master of Business Administration from Cornell University. - Robert E. Claypoole，于2024年1月加入Bioventus，担任总裁兼首席执行官，并担任Bioventus Inc.董事会成员。Claypoole先生从世界领先的医疗产品和解决方案公司M lnlycke Health Care（“M lnlycke”）加入Bioventus，自2021年7月起担任伤口护理执行副总裁。在担任这一职务时，克莱普尔先生对一项价值12亿美元的业务负有全部责任。在此之前，Claypoole先生曾于2017年3月至2021年7月在M lnlycke担任多个领导职务，包括M lnlycke执行副总裁兼美国总裁，以及M lnlycke Health Care US，LLC和M lnlycke Manufacturing US，LLC的官员。在2017年加入M lnlycke之前，Claypoole先生在被美敦力收购之前，曾在全球医疗保健技术公司美敦力有限公司（现为美敦力 PLC（NYSE：MDT））和Covidien担任过各种领导职务。Claypoole先生曾任肥胖与代谢健康全球副总裁兼总经理（2016年4月至2017年3月）和软组织修复与止血剂业务全球副总裁兼总经理（2012年12月至2016年4月）。在此之前，他在法国Trevoux担任全球营销副总裁后担任副总裁，执行运营。在法国任职之前，Claypoole先生是该公司内机和智能设备业务的美国市场营销副总裁。在2007年加入Covidien之前，Claypoole先生曾在强生的视力保健部门担任过各种营销职务，责任越来越大。Claypoole先生曾在ZetrOz Inc.（2014年1月至2016年1月）和围术期注册护士协会（2017年12月至2020年12月）的董事会任职。Claypoole先生获得了康奈尔大学的文学学士学位和工商管理硕士学位。
- Robert E. Claypoole,joined Bioventus in January 2024 as President and Chief Executive Officer and as a member of Bioventus Inc. Board. Mr. Claypoole joined Bioventus from Mlnlycke Health Care ("Mlnlycke"), a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care since July 2021. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business. Before that, Mr. Claypoole served in several leadership positions with Mlnlycke from March 2017 to July 2021, including Executive Vice President and President, US for Mlnlycke and as an Officer of Mlnlycke Health Care US, LLC and Mlnlycke Manufacturing US, LLC. Prior to joining Mlnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic Ltd. (now Medtronic plc (NYSE: MDT)), a global healthcare technology company, and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health (April 2016 to March 2017) and Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business (December 2012 to April 2016). Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company's Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson's Vision Care division. Mr. Claypoole previously served on the board of directors of ZetrOz Inc. (January 2014 to January 2016) and the Association of periOperative Registered Nurses (December 2017 to December 2020). Mr. Claypoole received his Bachelor of Arts and his Master of Business Administration from Cornell University.
- Guy P. Nohra
-
Guy P. Nohra自2006年8月担任董事。Nohra先生于1996年共同创立Alta Partners公司，这是一家投资于生命科学公司的风险投资公司，他自1996年担任Alta Partners公司的常务董事，Nohra先生也是Burr, Egan, Deleage & Co公司的合伙人，这是一个风险投资公司，他于1989年加盟。从1984年1月至1987年6月Nohra先生是Security Pacific Trading公司医疗产品的产品经理，这是一个消费和商业银行。目前，Nohra先生任职于许多私人公司的董事会，包括Carbylan生物外科公司，Coapt系统公司，PneumRx公司和Vertiflex公司，并是USGI医疗公司董事会的主席，此外，Nohra先生曾担任ATS Medical公司的董事会成员，该公司专注于心脏外科手术产品的制造，在2010年被一家医疗器械公司Medtronic公司收购，他也是Cutera公司董事会的成员，这是一个全球医疗器械公司。 Nohra先生还任职于医疗设备制造商协会（Medical Device Manufacturing Association）董事会，这是一个国家贸易组织，倡导医疗技术公司的创立。 Nohra先生拥有斯坦福大学历史学士学位和Chicago大学工商管理硕士学位。
Guy P. Nohra has served as director since August 2006. Mr. Nohra co-founded Alta Partners, a venture capital firm investing in life science companies in 1996 and has served as Managing Director of Alta Partners since 1996. Mr. Nohra was also a partner at Burr, Egan, Deleage & Co., a venture capital firm, which he joined in 1989. From January 1984 until June 1987 Mr. Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation, a consumer and commercial bank. Currently, Mr. Nohra serves on the board of directors of numerous private companies, including Carbylan Biosurgery, Inc., Coapt Systems, PneumRx, Inc. and Vertiflex, Inc., and is the Chairman of the Board of USGI Medical, Inc. In addition, Mr. Nohra previously served on the board of directors of ATS Medical, Inc., a company focused on the manufacture of cardiac surgery products, that was acquired by Medtronic, Inc., a medical device company, in 2010 and Cutera, Inc., a global medical device company. Mr. Nohra also serves on the board of directors of the Medical Device Manufacturing Association, a national trade organization that advocates for entrepreneurial medical technology companies. Mr. Nohra holds a B.A. in History from Stanford University and an M.B.A. from the University of Chicago. - Guy P. Nohra自2006年8月担任董事。Nohra先生于1996年共同创立Alta Partners公司，这是一家投资于生命科学公司的风险投资公司，他自1996年担任Alta Partners公司的常务董事，Nohra先生也是Burr, Egan, Deleage & Co公司的合伙人，这是一个风险投资公司，他于1989年加盟。从1984年1月至1987年6月Nohra先生是Security Pacific Trading公司医疗产品的产品经理，这是一个消费和商业银行。目前，Nohra先生任职于许多私人公司的董事会，包括Carbylan生物外科公司，Coapt系统公司，PneumRx公司和Vertiflex公司，并是USGI医疗公司董事会的主席，此外，Nohra先生曾担任ATS Medical公司的董事会成员，该公司专注于心脏外科手术产品的制造，在2010年被一家医疗器械公司Medtronic公司收购，他也是Cutera公司董事会的成员，这是一个全球医疗器械公司。 Nohra先生还任职于医疗设备制造商协会（Medical Device Manufacturing Association）董事会，这是一个国家贸易组织，倡导医疗技术公司的创立。 Nohra先生拥有斯坦福大学历史学士学位和Chicago大学工商管理硕士学位。
- Guy P. Nohra has served as director since August 2006. Mr. Nohra co-founded Alta Partners, a venture capital firm investing in life science companies in 1996 and has served as Managing Director of Alta Partners since 1996. Mr. Nohra was also a partner at Burr, Egan, Deleage & Co., a venture capital firm, which he joined in 1989. From January 1984 until June 1987 Mr. Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation, a consumer and commercial bank. Currently, Mr. Nohra serves on the board of directors of numerous private companies, including Carbylan Biosurgery, Inc., Coapt Systems, PneumRx, Inc. and Vertiflex, Inc., and is the Chairman of the Board of USGI Medical, Inc. In addition, Mr. Nohra previously served on the board of directors of ATS Medical, Inc., a company focused on the manufacture of cardiac surgery products, that was acquired by Medtronic, Inc., a medical device company, in 2010 and Cutera, Inc., a global medical device company. Mr. Nohra also serves on the board of directors of the Medical Device Manufacturing Association, a national trade organization that advocates for entrepreneurial medical technology companies. Mr. Nohra holds a B.A. in History from Stanford University and an M.B.A. from the University of Chicago.
- Martin P. Sutter
-
Martin P. Sutter，自2008年5月他一直担任董事。自1994年以来他一直是埃塞克斯兀兰健康Ventures的董事总经理，一家医疗保健的重点发展股权投资公司，并且是他共同创立的。他拥有超过30年的运营，营销，财务和风险投资管理经验。他目前担任QSpex技术公司，处方眼镜镜片制造商的董事会。他拥有路易斯安那州立大学工商管理科学学士学位以及休斯顿大学硕士学位。
Martin P. Sutter,Since 1985has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm. Educated in chemical engineering and finance, Mr. Sutter has more than 40 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration from the University of Houston.Other Current and Past Company Directorships, Trusteeships and Memberships: Board of Directors of Bioventus, Inc., a publicly held orthobiologics company focused on active healing therapies, biosurgical products and sports medicine; Board of Directors of Prolacta Bioscience, Inc., a privately held company which provides human milk-based nutritional products for critically ill, premature infants in neonatal intensive care units; and Board of Directors of MiMedx Group Inc., a publicly held regenerative medicine company with a specialized focus on tissue from the amniotic membrane and umbilical cord, with wide-ranging clinical applications across wound care and musculoskeletal impairments. Formerly on the Boards of Directors of the following EW Healthcare Partners' portfolio investments: ATS Medical later acquired by Medtronic, Inc.; BioForm Medical (later acquired by Merz GmbH & Co KGaA); LifeCell (later acquired by Kinetic Concepts); St. Francis Medical (later acquired by Kyphon, Inc./Medtronic, Inc.); Confluent Surgical (later acquired by Tyco International/Covidien); and Rinat Neurosciences (later acquired by Pfizer, Inc.). Mr. Sutter is also a former Trustee of the Culinary Institute of America. - Martin P. Sutter，自2008年5月他一直担任董事。自1994年以来他一直是埃塞克斯兀兰健康Ventures的董事总经理，一家医疗保健的重点发展股权投资公司，并且是他共同创立的。他拥有超过30年的运营，营销，财务和风险投资管理经验。他目前担任QSpex技术公司，处方眼镜镜片制造商的董事会。他拥有路易斯安那州立大学工商管理科学学士学位以及休斯顿大学硕士学位。
- Martin P. Sutter,Since 1985has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm. Educated in chemical engineering and finance, Mr. Sutter has more than 40 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration from the University of Houston.Other Current and Past Company Directorships, Trusteeships and Memberships: Board of Directors of Bioventus, Inc., a publicly held orthobiologics company focused on active healing therapies, biosurgical products and sports medicine; Board of Directors of Prolacta Bioscience, Inc., a privately held company which provides human milk-based nutritional products for critically ill, premature infants in neonatal intensive care units; and Board of Directors of MiMedx Group Inc., a publicly held regenerative medicine company with a specialized focus on tissue from the amniotic membrane and umbilical cord, with wide-ranging clinical applications across wound care and musculoskeletal impairments. Formerly on the Boards of Directors of the following EW Healthcare Partners' portfolio investments: ATS Medical later acquired by Medtronic, Inc.; BioForm Medical (later acquired by Merz GmbH & Co KGaA); LifeCell (later acquired by Kinetic Concepts); St. Francis Medical (later acquired by Kyphon, Inc./Medtronic, Inc.); Confluent Surgical (later acquired by Tyco International/Covidien); and Rinat Neurosciences (later acquired by Pfizer, Inc.). Mr. Sutter is also a former Trustee of the Culinary Institute of America.
- John A. Bartholdson
-
JohnA.Bartholdson自2000年6月以来一直在我们的董事会任职。Bartholdson自2008年联合创立Juniper Investment Company，LLC“Juniper”（一家私人投资管理公司）起担任合伙人。Bartholdson先生和Juniper也是Aetolian Investors，LLC（一家注册商品池运营商）的负责人。Bartholdson自2006年4月起担任Stonington Partners，Inc.（一家私人投资公司）合伙人和董事，自1997年6月起担任其他职位。从1994年到1995年，他曾任职Stonington Partners公司，担任分析师，随后进入研究生院。Bartholdson从1992年到1994年在MLCP（一家私人投资公司，Merrill Lynch&Co.全资子公司）任职。Bartholdson先生担任并曾担任众多私人控股公司的董事。Bartholdson先生在杜克大学（Duke University）获得学士学位，在斯坦福大学商学院（Stanford Graduate School of Business）获得工商管理硕士学位。Bartholdson在其他公司董事会薪酬、治理、审计和执行委员会任职的经验以及他自公司成立以来对公司发展的了解，使他成为董事会有价值的成员。他对我们公司的知识和他对董事会角色的透彻理解使他有资格在董事会任职。
John A. Bartholdson was appointed to Lincoln Educational Services Corporation Board of Directors on November 14, 2019 as a Series A Preferred Stock Director. Mr. Bartholdson is a co-founder and partner of Juniper Investment Company, LLC, a New York based private investment firm. Mr. Bartholdson serves as the Chairman of the board of directors of Theragenics Corporation, a privately held company. Previously, he has served as a member of the board of directors of Obagi Medical Products, Inc., a publicly traded company, as well as on the boards of numerous private companies. Prior to co-founding Juniper Investment Company, Mr. Bartholdson was a partner of Stonington Partners, Inc. where he worked from 1997 to 2011. Mr. Bartholdson received his B.A. from Duke University and his M.B.A. from Stanford Graduate School of Business. He has many years of experience leading and overseeing investments across a range of industries and has a successful record of managing investments in public companies. - JohnA.Bartholdson自2000年6月以来一直在我们的董事会任职。Bartholdson自2008年联合创立Juniper Investment Company，LLC“Juniper”（一家私人投资管理公司）起担任合伙人。Bartholdson先生和Juniper也是Aetolian Investors，LLC（一家注册商品池运营商）的负责人。Bartholdson自2006年4月起担任Stonington Partners，Inc.（一家私人投资公司）合伙人和董事，自1997年6月起担任其他职位。从1994年到1995年，他曾任职Stonington Partners公司，担任分析师，随后进入研究生院。Bartholdson从1992年到1994年在MLCP（一家私人投资公司，Merrill Lynch&Co.全资子公司）任职。Bartholdson先生担任并曾担任众多私人控股公司的董事。Bartholdson先生在杜克大学（Duke University）获得学士学位，在斯坦福大学商学院（Stanford Graduate School of Business）获得工商管理硕士学位。Bartholdson在其他公司董事会薪酬、治理、审计和执行委员会任职的经验以及他自公司成立以来对公司发展的了解，使他成为董事会有价值的成员。他对我们公司的知识和他对董事会角色的透彻理解使他有资格在董事会任职。
- John A. Bartholdson was appointed to Lincoln Educational Services Corporation Board of Directors on November 14, 2019 as a Series A Preferred Stock Director. Mr. Bartholdson is a co-founder and partner of Juniper Investment Company, LLC, a New York based private investment firm. Mr. Bartholdson serves as the Chairman of the board of directors of Theragenics Corporation, a privately held company. Previously, he has served as a member of the board of directors of Obagi Medical Products, Inc., a publicly traded company, as well as on the boards of numerous private companies. Prior to co-founding Juniper Investment Company, Mr. Bartholdson was a partner of Stonington Partners, Inc. where he worked from 1997 to 2011. Mr. Bartholdson received his B.A. from Duke University and his M.B.A. from Stanford Graduate School of Business. He has many years of experience leading and overseeing investments across a range of industries and has a successful record of managing investments in public companies.
- William A. Hawkins
-
William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及Minnesota Foundation大学的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
William A. Hawkins,is currently a Senior Advisor at EW Healthcare Partners (since 2017),including President and CEO of Immucor (2011–2015), Chairman and CEO of Medtronic (2002–2011), and President and CEO of Novoste Corporation (1998–2001). He serves as Chair of Bioventus, Inc. (since 2016) and on the board of MiMedx Group, Inc. (since 2020), with prior directorship at Avanos Medical (2015–2021). His private company board engagements include Virtue Labs, Enterra, Lacuna Medical, Critec Medical Corp., and Baebies, Inc. He holds a B.Sc. in Electrical and Biomedical Engineering from Duke University and an MBA from the University of Virginia's Darden School, and is a member of the National Academy of Engineering and AIMBE College of Fellows. - William A. Hawkins自2007年3月以来是Medtronic的董事，自2008年8月以来担任董事长兼首席执行官。他自2007年8月以来担任Medtronic的总裁兼首席执行官，之前从2004年5月到2007年8月担任Medtronic的总裁兼首席运营官。他从2002年1月到2004年5月担任Medtronic Vascular的高级副总裁和总裁。他从1998年到2002年担任Novoste Corporation的总裁兼首席执行官。他服务于杜克大学工程学院（the Duke University School of Engineering）的监事会和the Guthrie Theater以及Minnesota Foundation大学的董事会。在过去的五年里，他还担任Deluxe Corporation的董事。
- William A. Hawkins,is currently a Senior Advisor at EW Healthcare Partners (since 2017),including President and CEO of Immucor (2011–2015), Chairman and CEO of Medtronic (2002–2011), and President and CEO of Novoste Corporation (1998–2001). He serves as Chair of Bioventus, Inc. (since 2016) and on the board of MiMedx Group, Inc. (since 2020), with prior directorship at Avanos Medical (2015–2021). His private company board engagements include Virtue Labs, Enterra, Lacuna Medical, Critec Medical Corp., and Baebies, Inc. He holds a B.Sc. in Electrical and Biomedical Engineering from Duke University and an MBA from the University of Virginia's Darden School, and is a member of the National Academy of Engineering and AIMBE College of Fellows.
高管简历
中英对照 | 中文 | 英文- Katrina Church
Katrina Church自2020年8月起担任我们的首席合规官。在加入我们之前，Church女士曾在Merz集团公司担任公司法律顾问和合规职务，最近于2015年3月至2020年8月担任Merz Pharma GmbH&Co KGaA（一家私人制药公司）的全球合规官。Church从1998年6月到2008年12月担任Connetics Corporation（一家专业制药公司，2008年被Stiefel Laboratories，Inc.收购）执行Vice President and General Counsel。Church女士的职业生涯始于担任霍普金斯律师事务所（Hopkins&Carley）的律师，这是一家位于圣何塞的律师事务所。Church女士于2020年被提名为多个合规培训行业奖，并获得了2020年度最具影响力合规培训计划的2020年女性合规奖和Brandon Hall2020优秀培训金奖。Church女士拥有纽约大学法学院（New York University School of Law）法学博士学位和杜克大学（Duke University）比较文学文学文学学士学位，成绩优异。
Katrina Church has served as our Chief Compliance Officer since August 2020. Prior to joining us, Ms. Church served in corporate counsel and compliance roles within the Merz Group of companies, most recently as Global Compliance Officer for Merz Pharma GmbH & Co KGaA, a privately-held pharmaceutical company, from March 2015 to August 2020. From June 1998 to December 2008 Ms. Church was Executive Vice President and General Counsel of Connetics Corporation, a specialty pharmaceutical company that was acquired by Stiefel Laboratories, Inc. in 2008. Ms. Church began her career as an attorney at Hopkins & Carley, a San Jose-based law firm. In 2020 Ms. Church was nominated for several industry awards for compliance training and received the 2020 Women in Compliance Award for “Most Impactful Compliance Training Programme of the Year” and the Brandon Hall 2020 Gold Medal for Excellence in Training. Ms. Church holds a Juris Doctor from New York University School of Law and a Bachelor of Arts in Comparative Literature, magna cum laude, from Duke University.- Katrina Church自2020年8月起担任我们的首席合规官。在加入我们之前，Church女士曾在Merz集团公司担任公司法律顾问和合规职务，最近于2015年3月至2020年8月担任Merz Pharma GmbH&Co KGaA（一家私人制药公司）的全球合规官。Church从1998年6月到2008年12月担任Connetics Corporation（一家专业制药公司，2008年被Stiefel Laboratories，Inc.收购）执行Vice President and General Counsel。Church女士的职业生涯始于担任霍普金斯律师事务所（Hopkins&Carley）的律师，这是一家位于圣何塞的律师事务所。Church女士于2020年被提名为多个合规培训行业奖，并获得了2020年度最具影响力合规培训计划的2020年女性合规奖和Brandon Hall2020优秀培训金奖。Church女士拥有纽约大学法学院（New York University School of Law）法学博士学位和杜克大学（Duke University）比较文学文学文学学士学位，成绩优异。
- Katrina Church has served as our Chief Compliance Officer since August 2020. Prior to joining us, Ms. Church served in corporate counsel and compliance roles within the Merz Group of companies, most recently as Global Compliance Officer for Merz Pharma GmbH & Co KGaA, a privately-held pharmaceutical company, from March 2015 to August 2020. From June 1998 to December 2008 Ms. Church was Executive Vice President and General Counsel of Connetics Corporation, a specialty pharmaceutical company that was acquired by Stiefel Laboratories, Inc. in 2008. Ms. Church began her career as an attorney at Hopkins & Carley, a San Jose-based law firm. In 2020 Ms. Church was nominated for several industry awards for compliance training and received the 2020 Women in Compliance Award for “Most Impactful Compliance Training Programme of the Year” and the Brandon Hall 2020 Gold Medal for Excellence in Training. Ms. Church holds a Juris Doctor from New York University School of Law and a Bachelor of Arts in Comparative Literature, magna cum laude, from Duke University.
- Robert E. Claypoole
Robert E. Claypoole，于2024年1月加入Bioventus，担任总裁兼首席执行官，并担任Bioventus Inc.董事会成员。Claypoole先生从世界领先的医疗产品和解决方案公司M lnlycke Health Care（“M lnlycke”）加入Bioventus，自2021年7月起担任伤口护理执行副总裁。在担任这一职务时，克莱普尔先生对一项价值12亿美元的业务负有全部责任。在此之前，Claypoole先生曾于2017年3月至2021年7月在M lnlycke担任多个领导职务，包括M lnlycke执行副总裁兼美国总裁，以及M lnlycke Health Care US，LLC和M lnlycke Manufacturing US，LLC的官员。在2017年加入M lnlycke之前，Claypoole先生在被美敦力收购之前，曾在全球医疗保健技术公司美敦力有限公司（现为美敦力 PLC（NYSE：MDT））和Covidien担任过各种领导职务。Claypoole先生曾任肥胖与代谢健康全球副总裁兼总经理（2016年4月至2017年3月）和软组织修复与止血剂业务全球副总裁兼总经理（2012年12月至2016年4月）。在此之前，他在法国Trevoux担任全球营销副总裁后担任副总裁，执行运营。在法国任职之前，Claypoole先生是该公司内机和智能设备业务的美国市场营销副总裁。在2007年加入Covidien之前，Claypoole先生曾在强生的视力保健部门担任过各种营销职务，责任越来越大。Claypoole先生曾在ZetrOz Inc.（2014年1月至2016年1月）和围术期注册护士协会（2017年12月至2020年12月）的董事会任职。Claypoole先生获得了康奈尔大学的文学学士学位和工商管理硕士学位。
Robert E. Claypoole,joined Bioventus in January 2024 as President and Chief Executive Officer and as a member of Bioventus Inc. Board. Mr. Claypoole joined Bioventus from Mlnlycke Health Care ("Mlnlycke"), a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care since July 2021. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business. Before that, Mr. Claypoole served in several leadership positions with Mlnlycke from March 2017 to July 2021, including Executive Vice President and President, US for Mlnlycke and as an Officer of Mlnlycke Health Care US, LLC and Mlnlycke Manufacturing US, LLC. Prior to joining Mlnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic Ltd. (now Medtronic plc (NYSE: MDT)), a global healthcare technology company, and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health (April 2016 to March 2017) and Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business (December 2012 to April 2016). Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company's Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson's Vision Care division. Mr. Claypoole previously served on the board of directors of ZetrOz Inc. (January 2014 to January 2016) and the Association of periOperative Registered Nurses (December 2017 to December 2020). Mr. Claypoole received his Bachelor of Arts and his Master of Business Administration from Cornell University.- Robert E. Claypoole，于2024年1月加入Bioventus，担任总裁兼首席执行官，并担任Bioventus Inc.董事会成员。Claypoole先生从世界领先的医疗产品和解决方案公司M lnlycke Health Care（“M lnlycke”）加入Bioventus，自2021年7月起担任伤口护理执行副总裁。在担任这一职务时，克莱普尔先生对一项价值12亿美元的业务负有全部责任。在此之前，Claypoole先生曾于2017年3月至2021年7月在M lnlycke担任多个领导职务，包括M lnlycke执行副总裁兼美国总裁，以及M lnlycke Health Care US，LLC和M lnlycke Manufacturing US，LLC的官员。在2017年加入M lnlycke之前，Claypoole先生在被美敦力收购之前，曾在全球医疗保健技术公司美敦力有限公司（现为美敦力 PLC（NYSE：MDT））和Covidien担任过各种领导职务。Claypoole先生曾任肥胖与代谢健康全球副总裁兼总经理（2016年4月至2017年3月）和软组织修复与止血剂业务全球副总裁兼总经理（2012年12月至2016年4月）。在此之前，他在法国Trevoux担任全球营销副总裁后担任副总裁，执行运营。在法国任职之前，Claypoole先生是该公司内机和智能设备业务的美国市场营销副总裁。在2007年加入Covidien之前，Claypoole先生曾在强生的视力保健部门担任过各种营销职务，责任越来越大。Claypoole先生曾在ZetrOz Inc.（2014年1月至2016年1月）和围术期注册护士协会（2017年12月至2020年12月）的董事会任职。Claypoole先生获得了康奈尔大学的文学学士学位和工商管理硕士学位。
- Robert E. Claypoole,joined Bioventus in January 2024 as President and Chief Executive Officer and as a member of Bioventus Inc. Board. Mr. Claypoole joined Bioventus from Mlnlycke Health Care ("Mlnlycke"), a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care since July 2021. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business. Before that, Mr. Claypoole served in several leadership positions with Mlnlycke from March 2017 to July 2021, including Executive Vice President and President, US for Mlnlycke and as an Officer of Mlnlycke Health Care US, LLC and Mlnlycke Manufacturing US, LLC. Prior to joining Mlnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic Ltd. (now Medtronic plc (NYSE: MDT)), a global healthcare technology company, and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health (April 2016 to March 2017) and Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business (December 2012 to April 2016). Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company's Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson's Vision Care division. Mr. Claypoole previously served on the board of directors of ZetrOz Inc. (January 2014 to January 2016) and the Association of periOperative Registered Nurses (December 2017 to December 2020). Mr. Claypoole received his Bachelor of Arts and his Master of Business Administration from Cornell University.
- Mark L. Singleton
Mark L. Singleton，自2022年3月起担任Bioventus Inc.高级副总裁兼首席财务官。辛格尔顿先生此前曾于2021年2月至2022年3月期间在特种医疗设备提供商泰利福 Inc.（“泰利福”）担任美洲战略业务部门财务副总裁，在此之前，于2014年至2020年期间担任泰利福的血管战略业务部门财务副总裁。在加入泰利福之前，辛格尔顿先生曾在跨国科技公司联想集团有限公司担任多个领导职务，包括担任Think Business Group执行董事（2013-2014年）、西欧执行董事首席财务官（2011-2012年）、执行董事、北美首席财务官（2007-2011年）和董事、美国财务经理（2005-2007年）。辛格尔顿先生在普渡大学获得理学学士学位，在杜克大学Fuqua商学院获得工商管理硕士学位。
Mark L. Singleton,has served as Bioventus Inc. Senior Vice President and Chief Financial Officer since March 2022. Mr. Singleton previously served as Vice President of Finance, Americas Strategic Business Units at Teleflex Inc. ("Teleflex"), a provider of specialty medical devices, from February 2021 to March 2022 and prior to that, served as Teleflex's Vice President of Finance, Vascular Strategic Business Unit from 2014 to 2020. Prior to Teleflex, Mr. Singleton held multiple leadership roles at Lenovo Group Limited, a multinational technology company, including as Executive Director, Think Business Group Chief Financial Officer (2013-2014), Executive Director, Western Europe Chief Financial Officer (2011-2012), Executive Director, North America Chief Financial Officer (2007-2011) and Director, U.S. Finance Manager (2005-2007). Mr. Singleton received his Bachelor of Science from Purdue University and his Master of Business Administration from Duke University, Fuqua School of Business.- Mark L. Singleton，自2022年3月起担任Bioventus Inc.高级副总裁兼首席财务官。辛格尔顿先生此前曾于2021年2月至2022年3月期间在特种医疗设备提供商泰利福 Inc.（“泰利福”）担任美洲战略业务部门财务副总裁，在此之前，于2014年至2020年期间担任泰利福的血管战略业务部门财务副总裁。在加入泰利福之前，辛格尔顿先生曾在跨国科技公司联想集团有限公司担任多个领导职务，包括担任Think Business Group执行董事（2013-2014年）、西欧执行董事首席财务官（2011-2012年）、执行董事、北美首席财务官（2007-2011年）和董事、美国财务经理（2005-2007年）。辛格尔顿先生在普渡大学获得理学学士学位，在杜克大学Fuqua商学院获得工商管理硕士学位。
- Mark L. Singleton,has served as Bioventus Inc. Senior Vice President and Chief Financial Officer since March 2022. Mr. Singleton previously served as Vice President of Finance, Americas Strategic Business Units at Teleflex Inc. ("Teleflex"), a provider of specialty medical devices, from February 2021 to March 2022 and prior to that, served as Teleflex's Vice President of Finance, Vascular Strategic Business Unit from 2014 to 2020. Prior to Teleflex, Mr. Singleton held multiple leadership roles at Lenovo Group Limited, a multinational technology company, including as Executive Director, Think Business Group Chief Financial Officer (2013-2014), Executive Director, Western Europe Chief Financial Officer (2011-2012), Executive Director, North America Chief Financial Officer (2007-2011) and Director, U.S. Finance Manager (2005-2007). Mr. Singleton received his Bachelor of Science from Purdue University and his Master of Business Administration from Duke University, Fuqua School of Business.